Sumitomo Chemical told the Tokyo Stock Exchange on August 4 that its listed subsidiary, Sumitomo Pharma, had put out a formal response to a report about the drugmaker and its group, published a day earlier by Gotham City Research LLC. The parent's disclosure did little more than point investors to the subsidiary's own statement, which is where the substance sits.
Sumitomo Pharma's position is narrow but specific. The company says the report reflects the author's own views and was not issued by Sumitomo Pharma itself. It says its consolidated and standalone financial statements were prepared under Japanese law and applicable accounting standards, were audited under the Financial Instruments and Exchange Act and the Companies Act, and that its accounting auditor issued an unqualified opinion.
On the question that matters most to holders of the stock, restatement, the company is equally direct: as of the disclosure date, it has not confirmed the misstatements or improper accounting the report alleges, and it currently has no plans to amend financial statements it has already published. Sumitomo Pharma said it will keep making timely disclosures as the situation develops.
What the filing does not do is engage the report's specific claims line by line, at least in the text supplied to TDnet. It is a categorical denial backed by an audit history, not a rebuttal of individual figures. Whether Gotham City Research LLC's report identifies particular line items, subsidiaries, or accounting treatments is not something this disclosure addresses, and readers should treat the report's contents as allegations the company says it has found no basis to support, not as a settled matter either way.